Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Nov;134(2):309-13.
doi: 10.1046/j.1365-2249.2003.02273.x.

Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis

S Kagami  1 , T Kakinuma, H Saeki, Y Tsunemi, H Fujita, K Nakamura, T Takekoshi, M Kishimoto, H Mitsui, H Torii, M Komine, A Asahina, K Tamaki
Affiliations

Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis

S Kagami et al. Clin Exp Immunol. 2003 Nov.

Abstract

Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of T cells, eosinophils and macrophages in lesional skin. Recently, eotaxin-2/CCL24 and eotaxin-3/CCL26 were identified as CC chemokines that signal exclusively via the CCR3 receptor and have eosinophil-selective chemoattractant activity, as does eotaxin/CCL11. We previously reported that serum levels of thymus and activation-regulated chemokine (TARC)/CCL17 and macrophage-derived chemokine (MDC)/CCL22 were correlated with the severity of AD. In this report, we investigated the participation of eotaxin-2/CCL24 and eotaxin-3/CCL26 in AD, first measuring the serum levels of eotaxin-2/CCL24 and eotaxin-3/CCL26 in 30 patients with AD, 20 patients with psoriasis vulgaris and 20 healthy controls. The serum levels of eotaxin-3/CCL26 (but not eotaxin-2/CCL24) were significantly higher in patients with AD than in either healthy controls or patients with psoriasis vulgaris; furthermore, the eotaxin-3/CCL26 levels in patients with moderate and severe AD were significantly higher than eotaxin-3/CCL26 levels in patients with mild AD. The serum eotaxin-3/CCL26 levels tended to decrease after treatment, but there was no significant difference between groups. Moreover, the serum eotaxin-3/CCL26 levels were significantly correlated with the serum TARC/CCL17 and MDC/CCL22 levels, eosinophil numbers in peripheral blood and the scoring AD (SCORAD) index. Our study strongly suggests that serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, have a notable correlation with disease activity of AD and that eotaxin-3/CCL26, as well as TARC/CCL17 and MDC/CCL22, may be involved in the pathogenesis of AD.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Enzyme-linked immunosorbent assay (ELISA) results of eotaxin-2/CCL24 (a) and eotaxin-3/CCL26 (b) using sera of patients with atopic dermatitis (AD), patients with psoriasis vulgaris and control subjects. (c) Serum eotaxin-3/CCL26 levels of the three groups (mild, moderate and severe) of patients with AD.
Fig. 1
Fig. 1
Enzyme-linked immunosorbent assay (ELISA) results of eotaxin-2/CCL24 (a) and eotaxin-3/CCL26 (b) using sera of patients with atopic dermatitis (AD), patients with psoriasis vulgaris and control subjects. (c) Serum eotaxin-3/CCL26 levels of the three groups (mild, moderate and severe) of patients with AD.
Fig. 1
Fig. 1
Enzyme-linked immunosorbent assay (ELISA) results of eotaxin-2/CCL24 (a) and eotaxin-3/CCL26 (b) using sera of patients with atopic dermatitis (AD), patients with psoriasis vulgaris and control subjects. (c) Serum eotaxin-3/CCL26 levels of the three groups (mild, moderate and severe) of patients with AD.
Fig. 2
Fig. 2
Serum eotaxin-2/CCL24 (a) and eotaxin-3/CCL26 (b) levels of eight patients with atopic dermatitis (AD) were measured before and after treatment with topical corticosteroids and oral antihistamines.
Fig. 2
Fig. 2
Serum eotaxin-2/CCL24 (a) and eotaxin-3/CCL26 (b) levels of eight patients with atopic dermatitis (AD) were measured before and after treatment with topical corticosteroids and oral antihistamines.
See this image and copyright information in PMC

References

    1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venerol (Stock) 1980;92(Suppl.):44–7.
    1. Leung DYM. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol. 1997;107(Suppl.):25–30. - PubMed
    1. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001;107:535–41. - PubMed
    1. Kakinuma T, Nakamura K, Wakugawa M, et al. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol. 2002;127:270–3. - PMC - PubMed
    1. Jose PJ, Griffiths Johnson DA, Collins PD, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med. 1994;179:881–7. - PMC - PubMed